{
    "clinical_study": {
        "@rank": "72401", 
        "brief_summary": {
            "textblock": "The purpose of this study is to test the safety and effectiveness of a new non-nucleoside\n      reverse transcriptase inhibitor (NNRTI), (+)-calanolide A, in HIV-positive patients who have\n      never received anti-HIV treatment."
        }, 
        "brief_title": "A Study to Evaluate the Safety and Effectiveness of a New Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), (+)-Calanolide A, in HIV-Positive Patients Who Have Never Received Anti-HIV Treatment", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "HIV Seropositivity"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients are randomized into 2 cohorts, with Cohort 2 receiving a higher dosage than Cohort\n      1. Patients in each cohort receive either (+)-calanolide A or a placebo for 14 days,\n      followed by a 14-day follow-up period.  Following study treatment, patients may elect to\n      receive an open-label, 6-month course of anti-HIV drugs to be selected by and administered\n      under the care of the patient's physician."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        You may be eligible for this study if you:\n\n          -  Are HIV-positive.\n\n          -  Have a CD4 count of at least 250 cells/mm3.\n\n          -  Have an HIV count (viral load) of at least 5,000 copies/ml.\n\n          -  Are at least 18 years old.\n\n        Exclusion Criteria\n\n        You will not be eligible for this study if you:\n\n          -  Have received prescription or nonprescription medications within 14 days of study\n             entry, or if you will need to take any of these medications during the study.\n\n          -  Have ever received anti-HIV medications.\n\n          -  Test positive for hepatitis B.\n\n          -  Have received a blood (or red blood cell) transfusion within 3 months prior to study\n             entry.\n\n          -  Have severe diarrhea.\n\n          -  Have severe heart, liver, kidney, or neurological (brain and spinal cord) disease.\n\n          -  Have hemophilia or another blood disorder.\n\n          -  Have received certain medications or vaccines within 30 days prior to study entry.\n\n          -  Have received chemotherapy or radiation within 16 days prior to study entry, or if\n             you will need either of these during the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "32", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002243", 
            "org_study_id": "297A", 
            "secondary_id": "57CL-9802"
        }, 
        "intervention": {
            "intervention_name": "Calanolide A", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Calanolide A", 
                "Reverse Transcriptase Inhibitors"
            ]
        }, 
        "keyword": "Anti-HIV Agents", 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "331813405"
                    }, 
                    "name": "South Florida Bioavailability Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vero Beach", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32960"
                    }, 
                    "name": "Treasure Coast Infectious Disease Consultants"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }, 
                    "name": "Cook County Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "212011192"
                    }, 
                    "name": "Univ of Maryland Institute of Human Virology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02118"
                    }, 
                    "name": "Boston Med Ctr / Clinical Research Office"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10003"
                    }, 
                    "name": "Beth Israel Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15213"
                    }, 
                    "name": "Anderson Clinical Research / Inc"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37212"
                    }, 
                    "name": "Vanderbilt Univ Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Galveston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "775550835"
                    }, 
                    "name": "Univ of Texas / Med Branch at Galveston"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase 1B Dose-Range Study to Evaluate the Safety, Pharmacokinetics, and Effects of (+)-Calanolide A on Surrogate Markers in HIV-Positive Patients With No Previous Antiretroviral Therapy", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002243"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sarawak MediChem Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2000"
    }, 
    "geocoordinates": {
        "Anderson Clinical Research / Inc": "40.441 -79.996", 
        "Beth Israel Med Ctr": "40.714 -74.006", 
        "Boston Med Ctr / Clinical Research Office": "42.358 -71.06", 
        "Cook County Hosp": "41.878 -87.63", 
        "South Florida Bioavailability Clinic": "25.789 -80.226", 
        "Treasure Coast Infectious Disease Consultants": "27.639 -80.397", 
        "Univ of Maryland Institute of Human Virology": "39.29 -76.612", 
        "Univ of Texas / Med Branch at Galveston": "29.301 -94.798", 
        "Vanderbilt Univ Med Ctr": "36.166 -86.784"
    }
}